Alexandria Ratzki-Leewing, PhD

Adjunct Professor



  • Adjunct Professor, Department of Epidemiology and Biostatistics
  • Scientist, Department of Family Medicine
  • Director, Hypoglycemia Research Program, Diabetes Alliance, Centre for Studies in Family Medicine, Schulich School of Medicine & Dentistry

Research Interests

  • Type 1 and type 2 diabetes epidemiology
  • Hypoglycemia epidemiology
  • Pharmacoepidemiology
  • Real-world methods and data
  • Health survey design
  • Person-reported outcome measures

Research Clusters

Short Bio

Dr. Alexandria Ratzki-Leewing is a leading expert in real-world diabetes epidemiology, specializing on hypoglycemia as a side effect of insulin and secretagogue use. She has conducted research in over 12 countries and is currently a Principal Investigator of the InHypo-DM study in Canada, and the iNPHORM study in the United States: America’s largest prospective investigation on hypoglycemia risk. As a globally recognized key opinion leader, Dr. Ratzki-Leewing serves on multiple clinical and policy advisory boards, including the Steering Committee of the International Hypoglycaemia Study Group. Her work has been featured in the American Diabetes Association’s Standards of Care in Diabetes, as well as other major clinical practice guidelines. In 2023, the International Diabetes Center named her a 'Rising Star' for her outstanding contributions to diabetes research.


Selected Top 5 publications:

  1. Ratzki-Leewing A, Black JE, Kahkoska AR, et al. Incidence of Level 3 (severe) hypoglycaemia in a real-world cohort of adults with type 1 or 2 diabetes mellitus (iNPHORM, United States). Diabetes Obes Metab, 2023; doi: 1111/dom.15268. Online ahead of print.
  2. Ratzki-Leewing A, Black JE, Ryan BL, et al. Development and validation of a real-world model to predict one-year, recurrent Level 3 (severe) hypoglycaemia risk in adults with diabetes (the iNPHORM study, United States). Diabetes Obes Metab, 2023; 25(10):2910-2927.
  3. Ratzki-Leewing A, Ryan BL, Zou GY, et al. Predicting real-world hypoglycemia risk in American adults with type 1 or 2 diabetes mellitus prescribed insulin and/or secretagogues: Protocol for a prospective, 12-wave internet-based panel survey with email support (the iNPHORM [Investigating Novel Predictions of Hypoglycemia Occurrence Using Real-world Models] Study). J Med Internet Res, 2022; 11(2):e33726.
  4. Ratzki-Leewing A, Ryan B, Buchenberger J, et al. COVID-19 hinterland: Surveilling the self-reported impacts of the pandemic on diabetes management in the USA (cross-sectional results of the iNPHORM study). BMJ Open, 2021; 11(9):e049782.
  5. Ratzki-Leewing A, Harris S, Mequinant S, et al. The real-world crude incidence of hypoglycemia in adults with diabetes: Results of the InHypo-DM study, Canada. BMJ Open Diabetes Res Care, 2018; 6(1):000503